About the Journal

Download [This article belongs to Volume - 64, Issue - 03]

Abstract : In most CML patients, the break in chromosome 22 is restricted to an area of 5.8-kb termed M-bcr. M-bcr consists of five exons termed M-bcr exons b1-b5. These exons are actually located within the central region of the BCR gene and are equivalent to exons 12-16 (e12- e16) of this gene. Most breaks occur immediately downstream of exon 2 or 3 of the M-bcr region and result in b2a2 or b3a2 fusion transcripts. To study the Frequencies of BCR-ABL1 Fusion Transcripts among Chronic Myeloid Leukemia Patients. PubMed, SCOPUS, Web of Science, and Science Direct were systematically searched for relevant literature. Rayyan QRCI was employed throughout this comprehensive process. The frequency of various BCR-ABL1 fusion transcripts was as follows: e19a2, e1a2, e1a2 + e13a3, e1a2 + e14a3, e13a3 and e14a3. CML patients with e1a2 transcripts had higher rates of disease progression, resistance, or suboptimal response to imatinib and failed to achieve major molecular response. There is also higher frequency b3a2 than b2a2 and e1a2 transcripts in CML patients in Northeast Iran. There is frequent BCR-ABL1 transcripts among the studied population of all the mentioned studies and there is a significant relationship between gender and frequency of various BCR-ABL1 fusion transcripts.